Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prometic Life Sciences, a biopharmaceutical company, has received $0.73m follow-on purchase order under its supply agreement with Octapharma, a Swiss based plasma fractionation company.
Subscribe to our email newsletter
The order includes purchase of PrioClear, a prion capture resin incorporated into Octapharma’s manufacturing process for its solvent/detergent treated plasma product, Octaplas LG.
The resumption of PrioClear supply is likely to begin in the fourth quarter of 2011.
The plasma product is currently approved for marketing in four countries including Germany, Switzerland, Portugal and Australia.